Loading
AP
Adamas Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Papapetropoulos Spyridon, was filed 15 Mar 2021.
Adamas Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Adamas Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Nothing new has been filed by managers of Adamas Pharmaceuticals Inc in twelve months, the latest record being from 24 November 2021.
Our records for Adamas Pharmaceuticals Inc go back to 2016, with 18 purchases and 36 sales on the open market in total.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
135
Thresholds
n/a
Buy Volume
€7M
18 ops. · all time
Sell Volume
€7M
36 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
RevenueUS$64.1M
Net income-US$49.4M-77.1% margin
Last declaration on 24 November 2021
Declarations135 total
112,781 sharesCommon StockSEC:0001328143-21-000094:1
600,000 sharesCommon StockSEC:0001328143-21-000093:1
163,767 sharesCommon StockSEC:0001328143-21-000092:1
5,000 sharesCommon StockSEC:0001328143-21-000087:1
186,786 sharesCommon StockSEC:0001328143-21-000090:1
4,031,804 sharesCommon StockSEC:0001328143-21-000091:1
6,043 sharesCommon StockSEC:0001328143-21-000091:2
3,146 sharesCommon StockSEC:0001328143-21-000091:3
25,661 sharesCommon StockSEC:0001328143-21-000091:4
287,992 sharesCommon StockSEC:0001328143-21-000091:5
265,150 sharesCommon StockSEC:0001328143-21-000091:6
18,750 shares0Common StockSEC:0001328143-21-000090:0
75,000 shares0Common StockSEC:0001328143-21-000093:0
18,750 shares0Common StockSEC:0001328143-21-000092:0
16,000 sharesCommon StockSEC:0001328143-21-000087:0
202,000 sharesCommon StockSEC:0001328143-21-000086:0
10,000 sharesCommon StockSEC:0001328143-21-000095:0
10,000 sharesCommon StockSEC:0001328143-21-000091:0
5,000 sharesCommon StockSEC:0001328143-21-000094:0
25,000 sharesCommon StockSEC:0001328143-21-000088:0
20,975 sharesCommon StockSEC:0001328143-21-000089:0
6,200 shares@ US$5.1585100.0% of flowCommon StockSEC:0001328143-21-000067:0
2,000 shares@ US$5.17100.0% of flowCommon StockSEC:0001328143-21-000063:0
5,000 shares0Common StockSEC:0001328143-21-000058:0
5,000 shares0Common StockSEC:0001328143-21-000059:0
25 of 135 declarations
About Adamas Pharmaceuticals Inc
Adamas Pharmaceuticals Inc. was a U.S.-based specialty pharmaceutical company historically listed on the NASDAQ under the ticker ADMS before its acquisition by Supernus Pharmaceuticals, which was completed in November 2021. For French, Belgian, and Swiss investors, this is an important distinction: Adamas no longer trades as an independent public company, but its legacy remains relevant for SEC filings, including Form 4 insider transaction analysis and governance review.
The company was founded in Emeryville, California, and built its strategy around chronic neurological disorders, with a clear focus on central nervous system (CNS) diseases. Adamas positioned itself as a developer and commercializer of chrono-synchronous therapies designed to improve day-to-day functioning for patients living with disabling neurologic conditions. In practical terms, its business model was centered on high-value, specialty neurologic medicines rather than broad primary-care franchises.
Read moreShow less
Adamas’ commercial profile was anchored by two marketed products. GOCOVRI, an extended-release formulation of amantadine, was described as the first and only FDA-approved medicine indicated for both “OFF” episodes and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. OSMOLEX ER, another amantadine extended-release product, was approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adults. These products formed the core of Adamas’ revenue-generating platform in the United States, which was the company’s key market.
From a competitive standpoint, Adamas occupied a specialized niche rather than a large-scale diversified pharmaceutical position. Its differentiation came from the clinical and regulatory profile of GOCOVRI in Parkinson’s disease, especially the combination of dyskinesia and OFF-episode utility, which created a more defensible therapeutic story than a commodity generics model. That said, the company’s narrow product base also meant limited diversification, making execution and reimbursement dynamics especially important.
Recent major developments were dominated by the strategic acquisition by Supernus Pharmaceuticals. Supernus announced the deal in October 2021 and completed it in November 2021, bringing Adamas’ Parkinson’s-focused portfolio into a larger CNS platform. As a result, Adamas ceased to exist as an independent listed company on the NASDAQ market in the United States. For investors, that means any current references to ADMS are best understood in a historical and transactional context, particularly when reviewing legacy insider activity, filing history, and the evolution of the company’s asset base prior to integration.
